目前，各类流感药品销售已经出现增长。根据叮当快药数据，奥司他韦和速福达（玛巴洛沙韦）销量上 升比较明显，奥司他韦近七天销量增长237%，玛巴洛沙韦上涨180%。同时一些感冒退热、清热解毒、 止咳平喘以及鼻喷类的药物销量均有上涨。 国家流感中心披露的《中国流感监测周报》显示，11月10日至11月16日南、北方省份流感活动上升。其 中北方省份哨点医院报告的ILI%（流感样病例百分比）为7.0%，不仅高于前一周水平（6.2%），也高 于2022年、2023年和2024年同期水平（2.1%、5.8%和3.9%）。同时，日本、英国等地流感疫情持续， 活动性也高于往年同期水平。 近期，多家上市公司积极行动，应对流感季的到来。圣湘生物与阿里健康围绕呼吸道感染性疾病领域达 成合作，结合淘宝闪购推出"居家闪检"服务；精华制药布局有玛巴洛沙韦等产品，公司称将根据市场情 况适时调整生产节奏，保证市场供应；康缘药业抗感染和呼吸领域核心产品，在流感季节需求有显著增 长，公司正在加紧排产来满足日益增长的需求。 健康元在25日披露了公司进度最靠前的治疗流感的创新药玛帕西沙韦胶囊的进展，目前该产品已进入审 评后期，公司正积极推进商业化准备工 ...

Market Overview - The Shanghai Composite Index closed down 0.15% at 3864.18 points, while the Shenzhen Component Index rose 1.02% to 12907.83 points. The ChiNext Index increased by 2.14% to 3044.69 points, and the STAR Market 50 Index gained 0.99% to 1315.04 points. The total trading volume in the Shanghai and Shenzhen markets was 17833.46 billion [1]. Sector Performance - The AI concept stocks continued to show strength, with multiple stocks hitting the daily limit up, including Sanwei Tiandi [1]. - The retail sector also performed well, with stocks like Guangbai Co. reaching the daily limit up [1]. - Stocks related to flu treatment were active, with companies like Guangji Pharmaceutical also hitting the daily limit up [1]. Stock Movements - A total of 1692 stocks rose, while 3593 stocks fell, with 6 stocks hitting the daily limit down. The overall trading volume was 17971.90 billion, with a total of 5453 stocks traded [5]. - The number of stocks with a price increase of more than 7% was 75, while 110 stocks had an increase of 5-7% [5]. Notable Stocks - Xinhua Du (002264.SZ) achieved a limit up on the fourth consecutive day, driven by AI e-commerce and cross-border e-commerce themes [6]. - Sanwei Tiandi (301159.SZ) hit the limit up with a focus on AI intelligence and humanoid robots [6]. - Guangji Pharmaceutical (000952.SZ) reached the limit up for the third consecutive day, benefiting from flu-related products [6]. Retail Sector Insights - The Ministry of Industry and Information Technology, along with other government bodies, issued a plan to enhance the adaptability of supply and demand in consumer goods, further promoting consumption [5].

Market Overview - The Shenzhen Component Index and the ChiNext Index both opened lower but rose throughout the day, while the Shanghai Composite Index turned negative in the afternoon. By the close, the Shanghai Composite Index fell by 0.15%, the Shenzhen Component Index rose by 1.02%, and the ChiNext Index increased by 2.14%. Over 3,500 stocks in the market declined [1]. Pharmaceutical Sector - The pharmaceutical sector has seen a strong performance driven by two main catalysts: 1. A rapid increase in flu activity across the country since November, with sales of Oseltamivir surging by 237% and sales of other flu medications also seeing significant increases [2]. 2. A series of favorable policies aimed at promoting the high-quality development of the medical device industry, including 15 support measures released by Beijing's economic and information technology bureau [2][3]. Flu-Related Stocks - Flu-related stocks have been particularly active, with companies like Yunnan Baiyao and Huaren Health hitting their daily price limits. The demand for flu medications has reportedly increased by over 500% in recent weeks [5][6]. CPO and AI Chip Stocks - The CPO (Co-Packaged Optics) sector has seen significant gains, with companies like Changguang Huaxin and Saiwei Electronics experiencing substantial price increases. This is attributed to Meta's plans to rent TPU computing power from Google Cloud, indicating a strong demand for AI computing resources [7][8]. - AI chip stocks have also performed well, with companies like Aojie Technology and Cambricon Technologies seeing price increases. A report indicates that major cloud service providers are accelerating the development of AI ASICs, which is expected to drive significant capital expenditure in the coming years [9][10]. Robotics Sector - The humanoid robotics sector has gained traction, with companies like Sanwei Tiandi and World Robotics seeing price increases. The growth is supported by a 41.7% year-on-year increase in industrial robot sales, reflecting the accelerating integration of AI in manufacturing [11][12]. Market Sentiment and Future Outlook - Analysts from Dongwu Securities suggest that the market has limited room for further decline after recent adjustments, with expectations for a potential recovery starting in November. The focus is on AI applications and sectors benefiting from domestic policy support [13][15]. - Galaxy Securities notes that the current A-share valuations are relatively reasonable, with expectations for upward momentum in the market driven by improving fundamentals and supportive policies [14].

11月26日，A股三大指数走势分化，沪指午后震荡转跌，截至收盘，上证指数跌0.15%，深证成指涨 1.02%，创业板指涨2.14%。盘面上，CPO概念再度走强，长光华芯2连板，中际旭创大涨超13%。医药 股全线走强，流感、创新药概念领涨，粤万年青、华人健康、北大医药等多股涨停。零售股尾盘拉升， 东百集团、国光连锁等多股涨停。军工板块回调，航天发展跌停。此外，半导体、元器件、海南自贸概 念、人形机器人概念等板块涨幅居前，水产品、银行、旅游等板块跌幅居前。全市场个股跌多涨少， 3500只个股下跌，成交金额近1.8万亿元。 ...

Core Viewpoint - The three major indices in the Chinese stock market experienced collective gains, with the Shanghai Composite Index rising by 0.14%, the Shenzhen Component Index increasing by 1.61%, and the ChiNext Index up by 2.76% as of midday trading [1] Market Performance - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 1,143.9 billion yuan, a decrease of 39.2 billion yuan compared to the previous day [1] - Over 2,800 stocks in the market saw an increase in their prices [1] Sector Highlights - The CPO (Consumer Price Outlook) sector showed strong performance, with Longguang Huaxin hitting the daily limit up of 20%, and Zhongji Xuchuang rising over 14% [1] - The influenza sector also performed well, with stocks like Yue Wannianqing and Huaren Health reaching the daily limit up of 20% [1] - The semiconductor sector was active, with Mingwei Electronics hitting the daily limit up of 20% and Botong Integrated reaching the limit [1] Sector Adjustments - The military industry sector experienced a pullback, with Jianglong Shipbuilding dropping over 9% and China Shipbuilding Defense hitting the daily limit down [1] - The commercial aerospace sector saw a peak followed by a decline, with Jiuzhiyang falling over 10% and Aerospace Development hitting the daily limit down [1]

Core Viewpoint - The pharmaceutical sector has shown significant strength, with various sub-sectors such as pharmaceutical commerce, chemical pharmaceuticals, influenza, and innovative drugs leading the gains in the market [1][2]. Sector Performance - Pharmaceutical Commerce: Increased by 43.67% [2] - Cell Immunotherapy: Increased by 42.76% [2] - Chemical Pharmaceuticals: Increased by 2.74% [2] - Influenza: Increased by 2.61% [2] - Innovative Drugs: Increased by 2.48% [2] Notable Stocks - Huaren Health: Increased by 20.00%, with a total market value of 69.60 billion [3] - Haiwang Biological: Increased by 10.20%, with a total market value of 73.93 billion [3] - Ruikang Pharmaceutical: Increased by 10.00%, with a total market value of 48.00 billion [3] - Hainan Haiyao: Increased by 10.00%, with a total market value of 119.9 billion [3] Market Context - As of the report, the Shanghai Composite Index decreased by 0.03%, while the Shenzhen Component Index increased by 0.84% and the ChiNext Index increased by 1.52% [4][5]. - Over 2300 stocks in the market saw an increase, with nearly 60 stocks hitting the daily limit up [5]. Influenza Activity - There has been a rapid increase in influenza activity nationwide, with Beijing entering a high incidence period for respiratory infectious diseases [3]. - Sales of Oseltamivir surged by 237% in the past week, while sales of Favipiravir increased by 180% [3].

Core Viewpoint - The pharmaceutical sector experienced a significant rally on November 26, with various sub-sectors such as pharmaceutical commerce, chemical pharmaceuticals, influenza, and innovative drugs leading the gains [1]. Sector Performance - The following sectors showed notable increases: - Pharmaceutical Commerce: +3.67% - Horse Racing Concept: +3.08% - Cell Immunotherapy: +2.76% - Chemical Pharmaceuticals: +2.74% - Influenza: +2.61% - Pharmaceutical E-commerce: +2.51% - Consistency Evaluation of Generic Drugs: +2.49% - Innovative Drugs: +2.48% - Helicobacter Pylori Concept: +2.42% - Internet E-commerce: +2.33% - Hainan: +2.30% - Medical Services: +2.23% - Hainan Free Trade Zone: +2.20% - Hepatitis Concept: +2.20% - Biological Products: +2.19% [2]. Notable Stock Performances - Several stocks reached their daily limit: - Huaren Health: +20.00% - Haiwang Bio: +10.20% - People's Tongtai: +10.00% - Ruikang Pharmaceutical: +10.00% - Hainan Haiyao: +10.00% - Guangji Pharmaceutical: +10.00% [3][4]. Market Overview - As of the report, the Shanghai Composite Index fell by 0.03%, while the Shenzhen Component Index rose by 0.84%, and the ChiNext Index increased by 1.52% [5][6]. - Over 2,300 stocks in the market saw gains, with nearly 60 stocks hitting the daily limit [6]. Influenza Impact - There has been a rapid increase in influenza activity nationwide since November, with Beijing entering a high incidence period for respiratory infectious diseases. Sales of Oseltamivir surged by 237% in the past week, while the sales of Favipiravir increased by 180% [4].

Core Viewpoint - The flu-related stocks in the A-share market are experiencing significant activity, driven by a surge in demand for flu medications and testing services as the flu season peaks in various regions of China [1] Group 1: Stock Performance - Yue Wannianqing saw a rise of over 16%, while Kangzhi Pharmaceutical increased by over 12%, and Hainan Haiyao and Peking University Pharmaceutical achieved consecutive gains [1] - The stock performance of flu-related companies indicates a strong market response, with notable increases in share prices for several firms [2] Group 2: Market Demand - Demand for flu-related medications and online consultations has surged, particularly in Northeast, North China, and Northwest regions, with Southern cities also experiencing rapid growth [1] - Orders for specific antiviral medications have more than doubled since November, with Mabalosavir tablets increasing by over 110% and Oseltamivir phosphate granules by over 85% compared to the previous month [1] Group 3: Consumer Behavior - Data from Alibaba Health shows a significant increase in the attention and purchase volume of flu medications over the past two weeks, with a more than 500% increase in the number of buyers for antiviral drugs [1] - Mabalosavir has shown exceptional growth, with a 600% increase in the number of purchasers, indicating heightened consumer awareness regarding flu prevention and treatment [1]

每经AI快讯，11月26日，流感概念反复活跃，广济药业3连板，北大医药触及涨停，金迪克涨超10%， 海南海药涨超7%，特一药业、新华制药、金石亚药跟涨。 （文章来源：每日经济新闻） ...

Core Viewpoint - The flu-related stocks in the A-share market are experiencing significant activity, driven by a surge in demand for flu medications and testing, particularly in northern regions of China [1] Group 1: Market Activity - Flu concept stocks are active, with notable increases in share prices: Yue Wannianqing up over 16%, Kangzhi Pharmaceutical up over 12%, and Hainan Haiyao and Peking University Pharmaceutical achieving consecutive gains [1] - The demand for flu-related medications and online consultations has risen sharply, with a more than 100% increase in orders for specific antiviral drugs since November [1] Group 2: Sales Data - Orders for the antiviral drug Mabalosavir have increased by over 110% compared to the previous month, while orders for Oseltamivir phosphate granules have risen by over 85% [1] - The sales of flu testing kits have shown a month-on-month increase of over 900% [1] Group 3: Consumer Behavior - Data from Alibaba Health indicates a significant rise in the attention and purchase volume of flu season medications, with a more than 500% increase in the number of buyers for antiviral drugs [1] - Mabalosavir stands out with a purchase increase of over 600%, while the number of buyers for antiviral oral solutions has risen by 50% [1]